IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut plus ) advanced non-small cell lung cancer (NSCLC)
Zhou, C.; Wu, Y. L.; Chen, G.; Feng, J. F.; Liu, X.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S.; Lu, S.; Zhang, L.; OPTIMAL Investigators
刊名JOURNAL OF CLINICAL ONCOLOGY
2011-05-20
suppl.S期:15
收录类别SCI
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
语种英语
WOS记录号WOS:000208880302246
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63236
专题北京大学临床肿瘤学院
作者单位1.Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
2.Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
3.Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
4.Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
5.Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
6.Acad Mil Med Sci, Ctr Canc, Hosp 307, Beijing, Peoples R China
7.Tianjin Canc Hosp, Tianjin, Peoples R China
8.Bejiing Chest Hosp, Beijing, Peoples R China
9.Peking Univ, Canc Hosp, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
10.Tongji Univ, Affiliated Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
11.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
12.Shanghai Chest Hosp, Shanghai, Peoples R China
13.Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
推荐引用方式
GB/T 7714
Zhou, C.,Wu, Y. L.,Chen, G.,et al. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut plus ) advanced non-small cell lung cancer (NSCLC)[J]. JOURNAL OF CLINICAL ONCOLOGY,2011,suppl.S(15).
APA Zhou, C..,Wu, Y. L..,Chen, G..,Feng, J. F..,Liu, X..,...&OPTIMAL Investigators.(2011).Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut plus ) advanced non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY,suppl.S(15).
MLA Zhou, C.,et al."Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut plus ) advanced non-small cell lung cancer (NSCLC)".JOURNAL OF CLINICAL ONCOLOGY suppl.S.15(2011).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhou, C.]的文章
[Wu, Y. L.]的文章
[Chen, G.]的文章
百度学术
百度学术中相似的文章
[Zhou, C.]的文章
[Wu, Y. L.]的文章
[Chen, G.]的文章
必应学术
必应学术中相似的文章
[Zhou, C.]的文章
[Wu, Y. L.]的文章
[Chen, G.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。